Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ischemic Heart Disease: Overview

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Janus Subnanochannels in Metalloporphyrin-Based Conjugated Metal-Organic Frameworks Enable Ultrasensitive Humidity Monitoring.

ACS nano·2026

Same author

Larvicidal and adulticidal activities of Purpureocillium lilacinum Secondary Metabolites against the Malaria Vector Anopheles gambiae.

Research square·2026

Same author

AI-enhanced non-invasive monitoring of critical biochemical analytes in perioperative care: a review of signal processing and clinical applications.

Frontiers in physiology·2026

Same author

Association Between Intraoperative Hyperlactatemia and Infection After Cardiac Surgery With Cardiopulmonary Bypass: A Multicenter Retrospective Study.

World journal of surgery·2026

Same author

Nanocatalytic Mitochondrial Oxidative Stress Amplification and Mitophagy Disruption for Efficient Tumor Catalytic Therapy.

Small (Weinheim an der Bergstrasse, Germany)·2026

Same author

Highly Active Strontium Peroxide Nanoparticles Induce Alkalization/Oxidation to Potentiate Cancer Immuno-Metabolic Therapy.

ACS nano·2026

Search research articles

Related Experiment Video

Updated: Oct 17, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Ischemic Microenvironment-Responsive Therapeutics for Cardiovascular Diseases.

Xi Li¹, Yabing Zhang¹, Xiangyi Ren²

¹Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.

Advanced Materials (Deerfield Beach, Fla.)

|October 8, 2021

Summary

Cardiovascular diseases from ischemia are a global health concern. Nanotechnology offers novel drug delivery systems targeting the unique ischemic microenvironment (IME) for improved treatment of heart conditions.

Keywords:

cardiovascular diseases ischemic microenvironment nanomedicine stimuli-responsive drug delivery

More Related Videos

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice

Published on: August 25, 2023

Related Experiment Videos

Last Updated: Oct 17, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice

Published on: August 25, 2023

Area of Science:

Biomaterials Science
Nanotechnology
Cardiovascular Medicine

Background:

Cardiovascular diseases due to ischemia exhibit high morbidity and mortality globally.
Existing cardioprotective agents face challenges like low bioavailability and systemic side effects.
Nanotechnology presents advanced solutions for effective drug delivery in ischemia-related diseases.

Purpose of the Study:

To review state-of-the-art biomaterials responsive to the ischemic microenvironment (IME).
To explore stimuli-responsive strategies for targeted drug delivery to cardiomyocytes.
To discuss innovative approaches for treating myocardial ischemia.

Main Methods:

Review of recent literature on IME-responsive biomaterials.
Analysis of stimuli-responsive drug delivery strategies (ROS, pH, hypoxia, MMPs, platelets).
Summary of intelligent biomaterials for enhanced therapeutic benefits.

Main Results:

IME-specific characteristics enable targeted drug delivery systems.
Various stimuli-responsive strategies are being developed for myocardial ischemia treatment.
Intelligent biomaterials enhance drug efficacy and biocompatibility.

Conclusions:

IME-responsive biomaterials hold significant promise for treating myocardial ischemia.
Further development is needed to overcome limitations and challenges.
Innovative approaches aim for high effectiveness and biocompatibility in ischemic disease treatment.